Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 86-94 , May 2008

Clinical aspects of sentinel lymph node biopsy in melanoma

  • Charlotte E. Ariyan, MD, PhD
    • ,
  • Daniel G. Coit, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Daniel G. Coit, MD, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

References 

  1. Morton LT. Morton's Medical Bibliography (An annotated Check-list of Texts Illustrating the History of Medicine (Garrison and Morton)). Brookfield, VT: Scolar Press; 1991;
  2. Kinmonth JB. Lymphangiography in man; a method of outlining lymphatic trunks at operation. Clin Sci (Lond). 1952;11:13–20
  3. Sherman AI, Ter-Pogossian M. Lymph-node concentration of radioactive colloidal gold following interstitial injection. Cancer. 1953;6:1238–1240
  4. Fee HJ, Robinson DS, Sample WF, et al. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study. Surgery. 1978;84:626–632
  5. Holmes EC, Moseley HS, Morton DL, et al. A rational approach to the surgical management of melanoma. Ann Surg. 1977;186:481–490
  6. Eberbach MA, Wahl RL. Lymphatic anatomy: Functional nodal basins. Ann Plast Surg. 1989;22:25–31
  7. Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432–437
  8. Uren RF, Thompson JF, Howman-Giles R, et al. Melanoma metastases in triangular intermuscular space lymph nodes. Ann Surg Oncol. 1999;6:811
  9. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195–204
  10. O'Toole GA, Hettiaratchy S, Allan R, et al. Aberrant sentinel nodes in malignant melanoma. Br J Plast Surg. 2000;53:415–417
  11. Statius Muller MG, Hennipman FA, van Leeuwen PA, et al. Unpredictability of lymphatic drainage patterns in melanoma patients. Eur J Nucl Med Mol Imaging. 2002;29:255–261
  12. McHugh JB, Su L, Griffith KA, et al. Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2006;13:1216–1223
  13. Wanebo HJ, Harpole D, Teates CD. Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. Cancer. 1985;55:1403–1413
  14. de Wilt JH, Thompson JF, Uren RE, et al. Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck. Ann Surg. 2004;239:544–552
  15. Gould EA, Winship T, Philbin PH, et al. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77–78
  16. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466
  17. Little JH, Davis NC. Secondary malignant melanoma in lymph nodes: Incidence, time of occurrence, and mortality. Aust N Z J Surg. 1978;48:9–13
  18. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67:228–233
  19. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70
  20. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) (Intergroup Melanoma Surgical Trial). Ann Surg Oncol. 2000;7:87–97
  21. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263discussion 263-266
  22. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial (WHO Melanoma Programme). Lancet. 1998;351:793–796
  23. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma (Preliminary results). Cancer. 1978;41:948–956
  24. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627–630
  25. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–641
  26. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  27. Alex JC, Weaver DL, Fairbank JT, et al. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol. 1993;2:303–308
  28. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217–224
  29. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol. 2001;8:192–197
  30. Stojadinovic A, Allen PJ, Clary BM, et al. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg. 2002;235:92–98
  31. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology. 2004;36:478–484
  32. Scheri RP, Essner R, Turner RR, et al: Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14:2861-2866, 2077.
  33. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA. 1998;280:1410–1415
  34. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17:3238–3244
  35. Blaheta HJ, Ellwanger U, Shittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114:637–642
  36. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231:795–803
  37. Goydos JS, Patel KN, Shin WJ, et al. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg. 2003;196:196–204discussion 204-205
  38. Ribuffo D, Gradilone A, Vonella M, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol. 2003;10:396–402
  39. Kammula US, Ghossein R, Bhattacharya S, et al. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction—staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004;22:3989–3996
  40. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24:2849–2857
  41. Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: A systematic review and meta-analysis of prognosis. J Clin Oncol. 2007;25:1588–1595
  42. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  43. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12:282–288
  44. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488–1498
  45. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127:380–384
  46. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427–432
  47. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100–108
  48. Compton CC, Barnhill R, Wick MR, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med. 2003;127:1253–1262
  49. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302–309
  50. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927–932
  51. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129–1134
  52. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2007;7:160–165
  53. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges. 2008;6:198–203
  54. Jacobs IA, Chang CK, Salti GI. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg. 2004;70:59–62
  55. Ferrone CR, Panageas KM, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637–645
  56. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914–936
  57. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1988;83:1128–1135
  58. Busam KJ, Mujudar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2008;28:1518–1525
  59. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol. 2003;10:403–407
  60. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207–213
  61. Su LD, Fullen DR, Sondak VK, et al. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. 2003;97:499–507
  62. Murali R, Sharma RN, Thompson JF, et al. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol. 2008;15:302–309
  63. Gamblin TC, Edington H, Kirkwood JM, et al. Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol. 2006;13:1664–1670
  64. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513–520
  65. Cerroni L, Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol. 2001;23:237–241
  66. Kogut KA, Fleming M, Pappo AS, et al. Sentinel lymph node biopsy for melanoma in young children. J Pediatr Surg. 2000;35:965–966
  67. Neville HL, Andrassy RJ, Lally KP, et al. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg. 2000;35:961–964
  68. Toro J, Ranieri JM, Havlik RJ, et al. Sentinel lymph node biopsy in children and adolescents with malignant melanoma. J Pediatr Surg. 2003;38:1063–1065
  69. Butter A, Hui T, Chapdelaine J, et al. Melanoma in children and the use of sentinel lymph node biopsy. J Pediatr Surg. 2005;40:797–800
  70. Roaten JB, Partrick DA, Pearlman N, et al. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005;40:232–235
  71. Chao C, Martin RC, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259–264
  72. Lange JR, Palis BE, Chang DC, et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25:1363–1368
  73. Chagpar RB, Ross MI, Reintgen DS, et al. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. J Surg Res. 2007;143:164–168
  74. Leong SP, Donegan E, Heffernon W, et al. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–366
  75. Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg. 2002;95:385–388
  76. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212–223
  77. Morton DL, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  78. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101–108
  79. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12:282–288
  80. Bachter D, Michl C, Büchels H, et al. The predictive value of the sentinel lymph node in malignant melanomas. Recent Results Cancer Res. 2001;158:129–136
  81. Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134:542–547discussion 547-548
  82. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21:1326–1331
  83. Rousseau DL, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569–574
  84. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11:900–906
  85. Carlson GW, Murray DR, Hestley A, et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?. Ann Surg Oncol. 2003;10:408–415
  86. Caracó C, Celentano E, Lastoria S, et al. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol. 2004;11(suppl 3):198S–202S

PII: S0740-2570(08)00026-9

doi: 10.1053/j.semdp.2008.04.004

Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 86-94 , May 2008

Article Tools

* Image Usage & Resolution